# OnCo record idp-023 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/idp-023/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "idp-023" ;
  schema:name "IDP-023"@en ;
  schema:alternateName "g-NK cells"@en ;
  schema:description "IDP-023 is an experimental allogeneic natural killer cell therapy from Indapta Therapeutics, in phase 2 trials for relapsed or refractory multiple myeloma and relapsed or refractory non-Hodgkin lymphoma."@en ;
  schema:url <https://onco.cc/drugs/idp-023/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://indapta.com/>, <https://indapta.com/>, <https://indapta.com/>, <https://clinicaltrials.gov/api/v2/studies/NCT06119685>, <https://clinicaltrials.gov/search?intr=IDP-023> ;
  onco:status "phase-2" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Allogeneic natural killer (NK) cell therapy" ;
  onco:cancers <https://onco.cc/cancers/myeloma-relapsed-refractory/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:companies <https://onco.cc/companies/indapta-therapeutics/> ;
  onco:trials <https://onco.cc/trials/nct06119685/> .